Skip to main content
Eurobio Scientific logo

Eurobio Scientific — Investor Relations & Filings

Ticker · ALERS ISIN · FR0013240934 LEI · 969500IQEUEH806GE257 PA Manufacturing
Open in API
Filings indexed 198 across all filing types
Latest filing 2021-07-26 Earnings Release
Country FR France
Listing PA ALERS

About Eurobio Scientific

https://www.eurobio-scientific.com

Eurobio Scientific is an integrated company specializing in in vitro diagnostics (IVD). Its activities cover the entire value chain, from research and development to the manufacturing and commercialization of specialty diagnostic products. The company's core focus areas are transplantation, oncology, and infectious diseases. In transplantation, it provides reagents, software for transplant matching and chimerism monitoring, and culture media for cornea grafts. For oncology, it develops and manufactures prognostic genomic tests for breast and prostate cancer. The group also markets a comprehensive portfolio of molecular tests for detecting infectious diseases, alongside solutions for immunology, fertility, and dermatological conditions.

Recent filings

Filing Released Lang Actions
Eurobio Scientific: FIRST HALF TURNOVER REACHES € 95.7 MILLION, A 54% INCREASE
Earnings Release Classification · 98% confidence The document is a press release dated July 26, 2021, presenting the company's consolidated half-year turnover as at June 30, 2021. It details financial performance for the first half of the year, including revenue figures, growth rates, and commentary on business segments (COVID vs. non-COVID sales). This content structure—a summary of financial results for a period shorter than a year (H1 2021)—is characteristic of an Interim/Quarterly Report announcement, although this specific document is the initial release of those results. Since it provides the key financial highlights immediately, it fits the definition of an Earnings Release (ER). It is not the full, comprehensive report (IR), nor is it a transcript (CT) or a full annual report (10-K). The mention of the next financial meeting (Half-year results 2021: October 12, 2021) confirms this is a periodic financial update. H2 2021
2021-07-26 English
EUROBIO SCIENTIFIC : BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE CONTRACTE PAR EUROBIO SCIENTIFIC AVEC TP ICAP
Capital/Financing Update Classification · 99% confidence The document is titled "BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE CONTRACTE PAR EUROBIO SCIENTIFIC AVEC TP ICAP (Europe)" and is dated July 9, 2021, reporting on the first half of 2021 (semestriel/first semester). It details the status of a liquidity contract, including share counts and cash balances as of June 30, 2021, and transaction volumes for the first half of 2021. This content strongly aligns with the reporting requirements for a comprehensive financial report covering a period shorter than a year, which corresponds to an Interim/Quarterly Report (IR). Although it is a specific type of report (liquidity contract balance), its function as a periodic financial disclosure for a half-year period makes 'IR' the most appropriate classification among the provided options, rather than a general announcement (RPA/RNS) or a full annual report (10-K).
2021-07-09 French
Eurobio Scientific : modalités de participation à l’assemblée générale annuelle à huis-clos du 17 juin 2021
AGM Information Classification · 98% confidence The document title explicitly mentions 'modalités de participation à l'assemblée générale annuelle' (modalities for participation in the annual general meeting) and the date of the AGM (17 juin 2021). This content details how shareholders can attend or vote in the upcoming Annual General Meeting (AGM), which falls directly under the scope of AGM Information. Although it is an announcement about the meeting logistics rather than the meeting minutes or voting results themselves, the primary subject matter is the AGM structure. Given the options, AGM-R (AGM Information) is the most appropriate classification, as it relates directly to the event itself.
2021-06-15 French
Eurobio Scientific launches its COVID antigen self-test
Regulatory Filings Classification · 95% confidence The document is a press release dated June 2, 2021, announcing the launch of a new proprietary COVID antigen self-test (EBS 1005) by Eurobio Scientific. It details the product, regulatory exemptions received (ANSM, Germany), intended use, and performance characteristics. This type of announcement, focusing on a specific product launch, regulatory clearance, or operational update that is not a full financial report (10-K, IR) or a transcript (CT), fits best under the general category for regulatory or corporate announcements that don't fit elsewhere, which is Regulatory Filings (RNS). It is not an Earnings Release (ER) as it doesn't focus on financial results, nor is it a Capital/Financing Update (CAP) or Management Change (MANG). Given its nature as a specific corporate news announcement, RNS is the most appropriate classification.
2021-06-03 English
Eurobio Scientific lance la commercialisation de son auto-test COVID antigénique
Regulatory Filings Classification · 95% confidence The document is a press release dated June 2, 2021, announcing the commercialization of a new proprietary COVID-19 antigen self-test (EBS 1005) by Eurobio Scientific, including details about regulatory approval (ANSM derogation) and product specifications. This type of announcement, focusing on a specific product launch or significant business development that is not a full financial report (like 10-K or IR) or a standard earnings release (ER), fits best under the general category of Regulatory Filings (RNS) as a miscellaneous regulatory/business announcement, or potentially a Capital/Financing Update (CAP) if the launch implied a major strategic shift, but RNS is the most appropriate fallback for specific operational news releases that don't match other codes. Given the content is a product launch announcement, RNS (Regulatory Filings) is the best fit as it covers general regulatory announcements not covered elsewhere. It is too detailed for a simple RPA.
2021-06-02 French
Eurobio Scientific propose un nouveau test propriétaire pour la détection du virus SARS-CoV-2 et la caractérisation simultanée de ses nouvelles mutations d’intérêt
Regulatory Filings Classification · 95% confidence The document is a press release dated May 26, 2021, announcing the availability of a new proprietary diagnostic test (EurobioPlex SARS-CoV-2 SNPs) for detecting SARS-CoV-2 and characterizing its mutations. It details the product, its immediate availability as a RUO (Research Use Only) product, and the intention to seek regulatory clearance. This type of announcement, focusing on a new product launch or significant development rather than periodic financial results (like 10-K, ER, IR) or management changes (MANG), fits best under a general regulatory or corporate announcement category. Since it is not a formal financial report, a specific financing event, or a shareholder vote result, and it is a direct announcement of a corporate development, it is classified as a Regulatory Filing (RNS) as a general announcement category, although it shares characteristics with an Investor Presentation (IP) or Capital Update (CAP) if the product launch was tied to financing. Given the context of a press release announcing a new diagnostic tool availability, RNS serves as the most appropriate general regulatory announcement fallback.
2021-05-26 French

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.